On December 22, Warner Pharmaceuticals(688799) issued an announcement stating that the company recently received the "Drug Registration Certificate" for isoproterenol hydrochloride injection issued by the National Medical Products Administration.

This drug is an injectable preparation, available in 1ml:0.2mg and 5ml:1mg formulations. It is classified as a Class 3 chemical drug, and the approval conclusion indicates that it meets the relevant requirements for drug registration. Isoproterenol hydrochloride injection is primarily used to treat cardiogenic or septic shock, complete atrioventricular block, and cardiac arrest.

Obtaining the drug registration certificate will further enrich the company's formulation product portfolio and optimize its product structure. Although it will not have a significant impact on the company's performance in the short term, future sales may still be affected by various factors such as policy changes, market demand, and competition from similar drugs, and there is a certain degree of uncertainty.

In the first three quarters of 2025, Warner Pharmaceuticals achieved revenue of RMB 1.086 billion and net profit attributable to the parent company of RMB 207 million.

https://finance.eastmoney.com/a/202512223598358588.html